NEW YORK (GenomeWeb) – Agilent Technologies said this week that it has mad an adjustment to its second quarter 2014 GAAP net income. The firm said that it has lowered that figure to $139 million, or $.41 per share, from a previously reported $150 million, or $.45 per share. Agilent said the change was the result of an out-of-period adjustment for tax expense. It added that its Q2 2014 non-GAAP net income was unchanged at $244 million, or $.72 per share.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genomic analysis of Malaysian tuberculosis strain, database of bat genomes, and more.

An editorial appearing at The Scientist bemoans the high numbers of mitochondrial genome papers and suggests a different path for mitochondrial genome research.

Researchers and drug developers are excited about the potential of CRISPR-Cas9-based therapeutics, the Wall Street Journal reports.

US lawmakers want to develop a new incarnation of the National Children's Study, ScienceInsider reports.